“…RNAi is triggered in eukaryotic cells by double-stranded RNAs having 19e21 nucleotides (short interfering RNA, siRNA; Fire et al, 1998), which, when recognized as aberrant, induce a polyenzymatic process leading to degradation of homologous mRNAs (Hannon, 2002). For in vivo application, viral mediated expression of siRNAs, which takes place a few days after transduction (Bahi and Dreyer, 2012;Ortiz et al, 2010), allows stable long term RNAi, thus silencing the expression of the relative genes (Bahi et al, 2004(Bahi et al, , 2005Bahi and Dreyer, 2012;Ortiz et al, 2010;Scherr et al, 2003;Van den Haute et al, 2003). Viral mediated silencing of targeted proteins offers higher temporal (RNAi starts right after transduction of targeted cells) and spatial control (inoculation of defined volumes and concentrations of viral vectors restricts silencing to targeted areas) of manipulations, compared to conventional knockout or pharmacological strategies.…”